Muamera Zulcic

发表

A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis

D. Durden, Shweta Joshi, A. Singh, 2014, Molecular Cancer Research.

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

C. Glass, D. Durden, J. Garlich, 2019, Molecular Cancer Therapeutics.

Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype

D. Durden, M. Selman, A. Pardo, 2017, PloS one.

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma

Yoon-Jae Cho, M. Levy, D. Durden, 2016, PloS one.

Chapter 10 Novel Therapeutic Approaches for Neuroblastoma

D. Durden, Shweta Joshi, A. Singh, 2017 .

Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo

T. Ideker, Janusz Dutkowski, D. Durden, 2014, PloS one.

Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

P. Tamayo, C. Glass, D. Durden, 2020, Molecular Cancer Therapeutics.

A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis

D. Durden, Shweta Joshi, A. Singh, 2014, BMC Immunology.

A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis

D. Durden, Shweta Joshi, A. Singh, 2014, Molecular Cancer Research.